Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab With or Without Defactinib in Resectable Pancreatic Ductal Adenocarcinoma
NCT03727880Phase 2Completed
- Start
- Jun 2019
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of defactinib in pancreatic ductal adenocarcinoma (PDAC) (2 arms). Primary endpoint: Pathologic Complete Response Rate at 4 years. Started Jun 2019; status: completed.
02
Drugs
defactinib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03727880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03727880.